SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawGuruFocus · Oct 5, 2026
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawBusiness Wire · Oct 5, 2026
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Business Wire · Oct 5, 2026
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawGuruFocus · Oct 5, 2026
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYGuruFocus · Oct 5, 2026
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYPRNewsWire · Oct 5, 2026ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.48 | -$0.63 | Miss |
| May 15, 2026 | -$0.53 | -$0.61 | Miss |
| Mar 9, 2026 | -$0.42 | -$0.42 | Beat |
| Nov 10, 2025 | -$0.45 | -$0.52 | Miss |
| Aug 13, 2025 | -$0.41 | -$0.46 | Miss |
| May 14, 2025 | -$0.35 | -$0.35 | Beat |